Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupHodgkin LymphomaradiotherapyDiseaseHodgkin LymphomaSubgroupICD10C81.-MeSHSequenceChemotherapyChemo-substanceBrentuximab vedotinDacarbazineDoxorubicinVinblastineChemo-substanceBrentuximab vedotinDacarbazineDoxorubicinVinblastineChemo-substanceBrentuximab vedotinDacarbazineDoxorubicinVinblastineChemo-substanceBrentuximab vedotinDacarbazineDoxorubicinVinblastineNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronPegfilgrastimNo. Substances5Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeuropathyNeutropeniaPain only studiesPublicationAuthorKumar ADiseaseHodgkin Lymphom, Stadium I-II, ErstlinieOriginMemorial Sloan Kettering Cancer Center, New YorkProtocols in Revision 1 protocol foundProtocols under revision.Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2 / Radiation, Hodgkin Lymphoma (PID1951 V1.0)
